Bristol Myers Squibb Reports observational Data for Ciltacabtagene autoleucel in Eosinophilic esophagitis

Bristol Myers Squibb today announced observational results for ciltacabtagene autoleucel in patients with eosinophilic esophagitis. The study demonstrated that ciltacabtagene autoleucel improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of eosinophilic esophagitis and support the continued development of ciltacabtagene autoleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.